Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lexicon Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
LXRX
Nasdaq
2834
https://www.lexpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lexicon Pharmaceuticals Inc
Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call
- May 3rd, 2024 11:46 am
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
- May 3rd, 2024 8:07 am
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
- May 2nd, 2024 10:05 pm
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
- May 2nd, 2024 10:03 pm
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
- May 2nd, 2024 8:05 pm
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
- Apr 29th, 2024 1:00 pm
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
- Apr 29th, 2024 11:00 am
Lexicon Pharmaceuticals to Host 2024 Investor Day
- Apr 18th, 2024 12:00 pm
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
- Apr 16th, 2024 4:00 pm
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- Apr 3rd, 2024 12:00 pm
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
- Mar 25th, 2024 1:20 pm
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
- Mar 13th, 2024 4:45 pm
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
- Mar 12th, 2024 12:00 pm
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
- Mar 11th, 2024 12:25 pm
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
- Mar 11th, 2024 11:15 am
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
- Mar 11th, 2024 11:05 am
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
- Mar 11th, 2024 11:00 am
Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for
- Feb 29th, 2024 3:00 pm
15 Hot Penny Stocks On the Move
- Feb 22nd, 2024 5:58 pm
3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts
- Jan 31st, 2024 10:06 am
Scroll